Updates are available Correction dated 2025-03-24

Article History

Accepted: 2 October 2024

First Online: 7 November 2024

Change Date: 24 March 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41572-025-00610-9

Competing interests

: A.K.P. has a consulting relationship with Acadia Pharmaceuticals, Anavex, Ionis, Neurogene, and Taysha, and has previously had a contract researcher relationship with Acadia Pharmaceuticals. J.L.N. has received research funding from the National Institutes of Health, the International Rett Syndrome Foundation and the Rett Syndrome Research Trust, and has served as investigator for clinical trials conducted by Acadia Pharmaceuticals, GW Pharmaceuticals, Neuren Pharmaceuticals and Newron. J.L.N. has also received personal consultancy for Acadia Pharmaceuticals Inc., Analysis Group, Anavex, AveXis, GW Pharmaceuticals, Hoffmann-La Roche, Ionis Pharmaceuticals, Myrtelle, Neurogene, Newron Pharmaceuticals, Signant Health and Taysha Gene Therapies, and the preparation of CME activities for the France Foundation, MedEdicus, Medscape, PeerView Institute, Medscape and TotalCME; and served on the scientific advisory board of Alcyone Lifesciences; was a scientific cofounder of LizarBio Therapeutics; and is a member of a data safety monitoring board for clinical trials conducted by Ovid Therapeutics and Ultragenix. S.R.C. is currently the Chief Scientific Officer at Neurogene Inc. He received research funding from the Rett Syndrome Research Trust, Simons Initiative for the Developing Brain, Neurogene and Rettco Inc. He has received patent royalties relating to gene therapy products being developed for Rett syndrome. B.B.-Z. received research funding for clinical trials from Ultragenix and the Rett Syndrome Research Trust. She has been a consultant to Taysha in the past and is serving as a monitor for Neurogene gene therapy programme. A.V. is a consultant for Anavex and GW Pharmaceuticals, and has conducted clinical trials with Newron Pharmaceuticals. L.P.-M. has received research funding from the National Institutes of Health, the International Rett Syndrome Foundation, and the Rett Syndrome Research Trust. W.E.K. was the Chief Scientific Officer of Anavex Life Sciences Corp. He received funding from the International Rett Syndrome Foundation, the National Institutes of Health and the Centers for Disease Control and Prevention, and he has been a consultant for Anavex, AveXis, Acadia, Compass, EryDel/Quince, Neuren Pharmaceuticals, Newron, GW Pharmaceuticals, Marinus, Biohaven, Zynerba, Ovid Therapeutics, Stalicla and Tetra. He has conducted clinical trials with Neuren and Ipsen. W.A.G sits on the Scientific Advisory Board of the International Rett Syndrome Foundation and has received funding from the Australian National Health and Medical Research Council. J.K.I. declares no competing interests.